After looking at one important poster yesterday on multiple myeloma, it’s time to explore other equally interesting targets in other tumour types.
Some years reflect the inertia that hit oncology R&D with a lot of old data rehashed or they can be flooded with many me-too compounds. Not this year, there’s a lot to talk about and review… so much so that we may well have enough for three rounds of Gems from the Poster Halls, time permitting as ASCO is fast approaching!
Without much further ado, for round 1 we have explored eight posters spanning four companies with a variety of different targets including chemotherapy, targeted therapies and immunotherapies. I will say though, that the lines are being blurred as all of these modalities can impact the immune system, sometimes in unexpected ways.
What’s in store for today? A focus on biotech companies doing intriguing cancer research.
Companies mentioned: Infinity, Innate, Incyte, Agenus